

Docket # PF-0293-3 DIV

By: Mkny Kamp Printed: Nancy Ramos



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE REQUEST FOR FILING A PATENT APPLICATION UNDER 37 CFR 1.53(b)

Commissioner for Patents Box Patent Application Washington, D.C. 20231

Dear Sir:

Ū

m

Ų

m

m

This is a request for filing a **DIVISIONAL** application under 37 CFR 1.53(b) of pending prior application Serial No.09/265,294, filed on March 9, 1999, which is a divisional application of U.S. application Serial No. 09/100,851, filed June 19, 1998, now U.S. Patent No. 5,911,984, which is a divisional of U.S. application Serial No. 08/872,784, filed June 11, 1997, now U.S. Patent No. 5,776,753, all entitled HUMAN PEROXISOMAL THIOESTERASE.

- 1. X Enclosed is a specification corresponding to the prior application, U. S. Application Serial No.08/872,784 filed June 11, 1997, including the oath or declaration as originally signed. The specification does not contain any subject matter that would have been new matter in the prior application.
- With regard to the requirement of 37 CFR 1.821(e) which requires that a copy of the Sequence Listing in computer readable form (CRF) be submitted, Applicants state that the paper copy of the Sequence Listing for the instant divisional application is identical with the computer readable form filed with Serial No. 08/872,784, filed June 11, 1997, to which priority is claimed. In accordance with 37 C.F.R. §1.821(e), please use the computer readable form filed with U.S. Application Serial No. 08/872,784 as the computer readable form for the instant divisional application. It is understood that the Patent and Trademark Office will make the necessary change in application number and filing date for the computer readable form that will be used for the instant divisional application.
- 3. X Cancel in this application original claims 2-9, 12-21, and 23 before calculating the filing fee, without prejudice or disclaimer. Applicants submit that these claims were included in the application as filed in the interest of providing notice to the public of certain specific subject matter intended to be claimed, and are being canceled at this time in the interest of reducing filing costs. Applicants expressly state that these claims are not being canceled for reasons related to patentability, and are in fact fully supported by the specification as filed. Applicants expressly reserve the right to reinstate these claims or to add other claims



during prosecution of this application or a continuation or divisional application. Applicants expressly do not disclaim the subject matter of any invention disclosed herein which is not set forth in the instantly filed claims.

- 4. X The inventors of the invention being claimed in this application are: Jennifer L. Hillman, Purvi Shah, and Neil C. Corley.
- 5. X In accordance with 37 CFR 1.63(d), a copy of the originally signed declaration showing applicants' signatures as filed on June 11, 1997 is enclosed.
- 6. ___ Amend the specification by inserting after the title:
- 7. X The filing fee is calculated below:

Claims	Number Filed	Minus	Number Extra	Other Small Rate		Basic Fee \$710.00
Total Claims	20	-20	0	x \$18		\$ 0
Indep. Claims	3	-3	0	x \$80		\$ 0
Multiple Dependent Claim(s), if any +\$270					\$0	

TOTAL FILING FEE \$710.00

- 8. __ An extension of time in the above-named prior application has been requested and the fees therefore have been authorized in said application.
- 9. X Please charge Deposit Account No. **09-0108** in the amount of \$ 710.00.

The Commissioner is hereby authorized to charge any additional fees which may be required or credit any overpayment to Deposit Account No. <u>09-0108</u>.

A duplicate copy of this Request is enclosed.

- 10. X New formal drawings are enclosed.
- 11. X The prior application is assigned of record to <u>Incyte Pharmaceuticals, Inc.</u>, recorded on January 16, 1998, at reel 8929/frame 0266.
- 12. A preliminary amendment is enclosed.
- 13. X Also enclosed: Return Postcard, Information Disclosure Statement, List of Cited References (PTO-1449), Submission of Formal Drawings, Revocation and Power of Attorney.

14. X The power of attorney of the prior application is to:

Narinder S. Banait	Reg. No. 43,482
Lucy J. Billings	Reg. No. 36,749
Michael C. Cerrone	Reg. No. 39,132
Diana Hamlet-Cox	Reg. No. 33,302
Colette C. Muenzen	Reg. No. 39,784
Lynn E. Murry	Reg. No. 42,918
Danielle M. Pasqualone	Reg. No. 43,847
Susan K. Sather	Reg. No. 44,316
David G. Streeter	Reg. No. 43,168

- a. X A Certificate Under 37 C.F.R. §3.73(b), Revocation of Power of Attorney and Appointment of New Attorneys is attached.
- b. ___ Since the power does not appear in the original papers, a copy of the power in the prior application is enclosed.
- c. X Address all future correspondence to:

INCYTE GENOMICS, INC.
PATENT DEPARTMENT
3160 Porter Drive
Palo Alto, California 94304

Phone: (650) 855-0555, Fax: (650) 845-4166

Date: 18, () assuring 2001

By:

Shirley A Recipon

Reg. No. 47,016

Direct Dial Telephone: (650) 621-8555

 inve	ente	or(s)	


_ Assignee of complete interest

X Attorney or agent of record

___ Filed under 37 CFR 1.34(a)

Registration number if acting under 37 CFR 1.34(a) ______.





"Express Mail" mailing label number EL 743 379 939 US. I hereby certify that this document and referenced attachments are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR § 1.10, addressed to: Commissioner for Patents, Box Patent Application, Washington, D.C. 20231 on /- /8-0/

Printed: Nancy Ramos

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Hillman et al.

Title:

HUMAN PEROXISOMAL THIOESTERASE

Serial No.:

To Be Assigned

Filing Date:

Herewith

Examiner:

To Be Assigned

Group Art Unit:

To Be Assigned

Official Draftsperson

Commissioner for Patents Washington, D.C. 20231

SUBMISSION OF FORMAL DRAWINGS

Sir:

Transmitted herewith are Figure(s) 1A, 1B, 1C, 2A, 2B, 3A, and 3B, as seven (7) sheets of formal drawings for this application. Each sheet of drawing indicates the identifying indicia suggested in 37 CFR Section 1.84(c) on the reverse side of the drawings.

Applicants believe that no fee is due with this paper. However, if the Commissioner determines that a fee is necessary, the Commissioner is hereby authorized to charge any additional fees associated with this communication or credit any overpayment to Deposit Account No. 09-0108. A duplicate copy of this communication is enclosed.

If there are any questions regarding the above, the Examiner is invited to call the undersigned at 650-855-0555.

Respectfully submitted,

INCYTE GENOMICS, INC.

Reg. No. 47,016

Direct Dial Telephone: (650) 621-8555

3160 Porter Drive

Palo Alto, California 94304

Phone: (650) 855-0555 Fax: (650) 845-4166

72202